McKesson Corporation awarded $902M VA contract for pharmaceutical prime vendor services in FY2023

Contract Overview

Contract Amount: $901,976,192 ($902.0M)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2023-09-01

End Date: 2023-09-30

Contract Duration: 29 days

Daily Burn Rate: $31.1M/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2023 SEPTEMBER

Place of Performance

Location: IRVING, DALLAS County, TEXAS, 75039

State: Texas Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $902.0 million to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2023 SEPTEMBER Key points: 1. The contract represents a significant portion of the VA's pharmaceutical spending, highlighting the critical role of prime vendors. 2. Full and open competition was utilized, suggesting a robust market for these services. 3. The contract's duration of 29 days indicates a short-term or task-order-based award within a larger framework. 4. The firm-fixed-price contract type aims to provide cost certainty for the government. 5. Analysis of the per-unit cost is crucial to benchmark value against similar pharmaceutical supply contracts. 6. The geographic focus on Texas (TX) for this specific award warrants further investigation into broader distribution networks.

Value Assessment

Rating: good

The award of over $900 million to McKesson Corporation for pharmaceutical prime vendor services by the Department of Veterans Affairs is substantial. While specific performance metrics and value-for-money assessments require deeper analysis of the underlying task orders, the scale of the contract suggests a significant operational requirement. Benchmarking this against other large-scale pharmaceutical distribution contracts, particularly those managed by the Department of Defense or other federal health agencies, would provide a clearer picture of its relative value. The firm-fixed-price structure is a positive indicator for cost control.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that multiple qualified vendors had the opportunity to bid. The specific number of bidders is not provided in this summary, but the use of full and open competition generally fosters a competitive environment, which can lead to better pricing and service offerings for the government. This approach is typically preferred for large-scale procurements to ensure the government receives the best value.

Taxpayer Impact: The use of full and open competition is beneficial for taxpayers as it encourages a wider range of potential suppliers to compete, driving down prices and improving the quality of services offered.

Public Impact

Veterans across the nation will benefit from timely and reliable access to essential pharmaceuticals through the VA's supply chain. The contract ensures the continuous availability of a wide range of pharmaceutical preparations, supporting the healthcare needs of the veteran population. While the award is specific to Texas, the services provided are integral to the VA's national healthcare delivery system. This contract supports jobs within the pharmaceutical distribution and logistics sectors, contributing to the broader healthcare workforce.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

The short duration of the award (29 days) raises questions about whether this is a bridge contract or a specific task order within a larger, multi-year agreement.
Lack of detailed performance metrics in the summary makes it difficult to assess the contractor's past performance and potential risks.
The concentration of this large award in Texas might indicate regional supply chain considerations that could impact national distribution efficiency.

Positive Signals

The award to a well-established prime vendor like McKesson suggests a level of confidence in their ability to meet critical pharmaceutical needs.
The use of a firm-fixed-price contract type provides budgetary certainty for the Department of Veterans Affairs.
Full and open competition indicates a healthy market and potential for competitive pricing, which is a positive signal for value.

Sector Analysis

The pharmaceutical prime vendor (PPV) program is a critical component of the federal government's strategy to ensure a stable and cost-effective supply of pharmaceuticals. This sector is characterized by large, complex supply chains, significant regulatory oversight, and the involvement of major global manufacturers and distributors. The Department of Veterans Affairs, as a major healthcare provider, relies heavily on such contracts to meet the medical needs of its beneficiaries. Spending in this area is substantial across various federal agencies, including the Department of Defense and the Health Resources and Services Administration.

Small Business Impact

The provided data does not indicate any specific small business set-aside provisions or subcontracting goals for this particular award. As a large prime vendor contract, it is possible that subcontracting opportunities may exist for specialized logistics or distribution services, but this would need to be confirmed through a more detailed review of the contract terms. The absence of explicit small business considerations in the summary warrants further inquiry into the contractor's subcontracting plans.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Veterans Affairs' contracting and program management offices. Accountability measures are typically embedded within the contract's terms and conditions, including performance standards, reporting requirements, and payment schedules. Transparency is generally facilitated through contract award databases and public reporting mechanisms. The VA's Office of Inspector General would have jurisdiction to investigate any potential fraud, waste, or abuse related to this contract.

Related Government Programs

Department of Defense Pharmaceutical Prime Vendor Program
Federal Supply Schedule (FSS) Pharmaceutical Contracts
VA National Acquisition Center Contracts
Strategic Sourcing for Pharmaceuticals

Risk Flags

Potential for supply chain disruption
Price volatility of pharmaceuticals
Contractor performance risk
Cybersecurity vulnerabilities

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $902.0 million to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2023 SEPTEMBER

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $902.0 million.

What is the period of performance?

Start: 2023-09-01. End: 2023-09-30.

What is McKesson Corporation's track record with the Department of Veterans Affairs and other federal agencies for similar pharmaceutical prime vendor contracts?

McKesson Corporation is a major player in the pharmaceutical distribution industry and has a long-standing relationship with the Department of Veterans Affairs (VA) and other federal agencies. They have historically held significant prime vendor contracts, including those with the VA's Pharmaceutical Prime Vendor (PPV) program. Their track record typically involves managing complex supply chains, ensuring timely delivery of a vast array of medications, and adhering to stringent regulatory requirements. While specific performance details for individual contracts are often proprietary or found in internal agency evaluations, McKesson's continued success in securing large federal contracts suggests a generally positive performance history. However, like any large contractor, they may have faced scrutiny or performance issues on specific contracts over time, which would be detailed in agency performance reports or Inspector General findings.

How does the awarded price of $901,976,191.7 compare to the estimated value or benchmark for similar pharmaceutical prime vendor contracts?

The awarded value of $901,976,191.7 for a 29-day period (September 2023) represents a very high daily expenditure, approximately $31 million per day. To benchmark this effectively, one would need to compare it against the daily or monthly spending rates of similar Pharmaceutical Prime Vendor (PPV) contracts awarded by the VA or other large federal health agencies like the Department of Defense. The 'br': 31102627 value likely represents a benchmark or a previous award value, which is close to the daily burn rate calculated here. A comprehensive comparison would involve analyzing the scope of services, the breadth of pharmaceuticals covered, and the specific delivery requirements. Without more context on the specific services covered by this $902M award (e.g., if it covers a full year's worth of a specific region's needs or a specific type of pharmaceutical), a direct comparison is challenging. However, the magnitude suggests it's a critical and high-volume contract.

What are the primary risks associated with this contract, and what mitigation strategies are in place?

Primary risks associated with this large pharmaceutical prime vendor contract include supply chain disruptions (due to manufacturing issues, natural disasters, or geopolitical events), potential for price volatility of pharmaceuticals, cybersecurity threats to sensitive data, and contractor performance issues leading to stock-outs or delivery delays. Mitigation strategies typically involve robust inventory management systems, diversification of supply sources, strong contract performance clauses with penalties for non-compliance, regular performance reviews, and contingency planning for disruptions. The VA likely has established protocols for monitoring McKesson's performance, ensuring compliance with regulations, and maintaining adequate stock levels to prevent shortages for veterans. Cybersecurity measures are also paramount given the sensitive nature of pharmaceutical data and patient information.

How effective is the Pharmaceutical Prime Vendor (PPV) program in ensuring the VA provides timely and cost-effective access to necessary medications for veterans?

The Pharmaceutical Prime Vendor (PPV) program is generally considered effective by the VA for ensuring timely and cost-effective access to a broad formulary of medications. These contracts leverage the extensive distribution networks and purchasing power of large prime vendors like McKesson, which can lead to economies of scale and competitive pricing compared to direct procurement of every individual drug. The program streamlines the acquisition process, reduces administrative burden, and helps maintain adequate stock levels, which is crucial for patient care. However, effectiveness can vary based on contract specifics, vendor performance, and the dynamic nature of pharmaceutical markets. Continuous monitoring, performance evaluations, and competitive re-competition of these contracts are essential to maintain and enhance their effectiveness.

What are the historical spending patterns for pharmaceutical prime vendor services by the Department of Veterans Affairs over the past five fiscal years?

Historical spending patterns for pharmaceutical prime vendor services by the Department of Veterans Affairs (VA) have shown a consistent and significant investment in these contracts. While the exact figures fluctuate annually based on healthcare needs, drug pricing trends, and contract awards, the VA typically spends billions of dollars each fiscal year on pharmaceuticals. Prime vendor contracts, such as the one awarded to McKesson, represent a substantial portion of this spending. Over the past five fiscal years, the VA's pharmaceutical budget has generally increased, reflecting growing healthcare demands and the rising cost of medications. The PPV program has been a cornerstone of the VA's pharmaceutical supply chain strategy, indicating sustained reliance and significant financial commitment to these services.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $901,976,192

Exercised Options: $901,976,192

Current Obligation: $901,976,192

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline